Cerity Partners’s AbCellera Biologics ABCL Stock Holding History

Cerity Partners’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Sell	39,799 -12,500	-24%	-$61.1K	﹤0.01%	2759
2026 Q1	$183K	Buy	52,299 +242	+0.5%	+$871	﹤0.01%	2900
2025 Q4	$178K	Sell	52,057 -1,000	-2%	-$4.46K	﹤0.01%	2667
2025 Q3	$267K	Hold	53,057	–	–	﹤0.01%	2358
2025 Q2	$182K	Hold	53,057	–	–	﹤0.01%	2379
2025 Q1	$118K	Hold	53,057	–	–	﹤0.01%	2304
2024 Q4	$145K	Hold	53,057	–	–	﹤0.01%	2290
2024 Q3	$138K	Buy	53,057 +32,500	+158%	+$90.1K	﹤0.01%	2387
2024 Q2	$60.8K	Sell	20,557 -18,000	-47%	-$68.1K	﹤0.01%	2158
2024 Q1	$175K	Buy	38,557 +18,000	+88%	+$91.8K	﹤0.01%	2135
2023 Q4	$117K	Hold	20,557	–	–	﹤0.01%	1773
2023 Q3	$94.6K	Hold	20,557	–	–	﹤0.01%	1334
2023 Q2	$133K	Buy	+20,557	New	+$140K	﹤0.01%	1524
2021 Q3	–	Sell	-17,000	Closed	-$374K	–	683
2021 Q2	$374K	Buy	+17,000	New	+$469K	0.01%	527

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Cerity Partners's ABCL Position: Q2 2026 in Review

Cerity Partners reduced its AbCellera Biologics (ABCL) stake by 24% in Q2 2026, selling an estimated $61.1K and leaving 39,799 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #2759.

Cerity Partners first reported a position in ABCL in Q2 2021 and has held it in 14 quarters since. The position peaked at $374K in Q2 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Cerity Partners held 39,799 shares of AbCellera Biologics worth $312K as of Q2 2026.
Cerity Partners sold 12,500 AbCellera Biologics shares in Q2 2026, an estimated $61.1K.
AbCellera Biologics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2759 holding.
Cerity Partners first reported a position in AbCellera Biologics in Q2 2021 and has held it in 14 quarters since.
Cerity Partners's AbCellera Biologics position peaked at $374K in Q2 2021.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.